Engimmune Therapeutics is a Basel, Switzerland-based biotech developing novel T-cell receptor (TCR)-based therapeutics using a platform that combines genome editing, functional high-throughput screening, deep sequencing and machine learning. Its platform aims to engineer potent and specific TCR-T cell and soluble TCR therapies, with lead products focused on oncology and potential to expand into autoimmune diseases. The company is a spinout from the lab of Prof Sai Reddy at ETH Zurich and lists Dr Rodrigo Vazquez-Lombardi as Chief Scientific Officer and Søren Mouritsen as CEO. Engimmune intends to use its recent funding to further build its pipeline, expand the research team in Switzerland and establish a presence in Denmark, with a focus on GMP-certified manufacturing, clinical development and regulatory affairs. The platform is designed to address key efficacy and safety challenges that currently limit the potential of TCR-T cell and soluble TCR therapeutics. The company announced the appointment of TCR pioneer Dr Bent Jakobsen as Chairman of the Board.

Total raised

$16M

Funding rounds

1

Latest round

Seed

Latest activity

May 2022